Last reviewed · How we verify
DWP212525 100mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
DWP212525 100mg (DWP212525 100mg) — Daewoong Pharmaceutical Co. LTD..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DWP212525 100mg TARGET | DWP212525 100mg | Daewoong Pharmaceutical Co. LTD. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DWP212525 100mg CI watch — RSS
- DWP212525 100mg CI watch — Atom
- DWP212525 100mg CI watch — JSON
- DWP212525 100mg alone — RSS
Cite this brief
Drug Landscape (2026). DWP212525 100mg — Competitive Intelligence Brief. https://druglandscape.com/ci/dwp212525-100mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing